<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000801.v1.p1" parentStudy="phs000801.v1.p1" createDate="2014-09-17" modDate="2015-04-20">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Sonja Berndt</td><td>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Principal Investigator</td><td>Nathaniel Rothman</td><td>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Principal Investigator</td><td>Stephen Chanock</td><td>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Study Representative</td><td>Qing Lan</td><td>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Study Representative</td><td>Lauren Teras</td><td>Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>NCI Non-Hodgkin Lymphoma GWAS</StudyNameEntrez>
	<StudyNameReportPage>National Cancer Institute (NCI) Non-Hodgkin Lymphoma Genome-wide Association Study (GWAS)</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Cohort</StudyType>
		<StudyType>Case-Control</StudyType>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Within the framework of the International Lymphoma Epidemiology Consortium (InterLymph) Consortium and NCI-sponsored Cohort Consortium, investigators from 22 studies came together to conduct a genome-wide association study (GWAS) of non-Hodgkin lymphoma (NHL). The goal of the study was to identify common genetic variants associated with the risk of NHL. As described previously (Berndt SI et al., Nature Genetics, 2013, PMID: <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23770605">23770605</a> ), cases and controls from 22 studies, including nine prospective cohort studies, eight population-based case-control studies, and five clinic or hospital-based case-control studies were included in this effort. Cases of NHL were ascertained from cancer registries, clinics or hospitals, or through self-report verified by medical and pathology reports. The phenotype information for all NHL cases was reviewed centrally at the InterLymph Data Coordinating Center and harmonized according to the hierarchical classification proposed by the InterLymph Pathology Working Group based on the World Health Organization (WHO) classification (2008). Controls were frequency matched to cases on age and gender by study, and the study was limited to subjects of European ancestry. Participants were genotyped using the Illumina Omni Express.</p> <p><b>The NCI Non-Hodgkin Lymphoma GWAS is utilized in the following dbGaP sub-study.</b> To view genotypes and derived variables collected in these sub-study, please click on the following sub-study below or in the "Sub-studies" box located on the right hand side of this top-level study page <a href="study.cgi?study_id=phs000801">phs000801</a> NCI Non-Hodgkin Lymphoma GWAS. <ul> <li><a href="study.cgi?study_id=phs000802">phs000802</a> NCI Non-Hodgkin Lymphoma GWAS: CLL Cases</li> <li><a href="study.cgi?study_id=phs000818">phs000818</a> NCI Non-Hodgkin Lymphoma GWAS: Control Set</li> </ul> </p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>The study included pathology-confirmed cases of NHL and matched controls from 22 studies. Only cases and controls who self-reported as Caucasian (or non-Hispanic Caucasian) were eligible for this study.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="23770605"/>
		</Publication>
		<Publication>
			<Pubmed pmid="25261932"/>
		</Publication>
		<Publication>
			<Pubmed pmid="25279986"/>
		</Publication>
		<Publication>
			<Pubmed pmid="25569183"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Lymphoma, Non-Hodgkin"/>
		<Disease vocab_source="MESH" vocab_term="Leukemia, Lymphocytic, Chronic, B-Cell"/>
		<Disease vocab_source="MESH" vocab_term="Lymphoma, Large B-Cell, Diffuse"/>
		<Disease vocab_source="MESH" vocab_term="Lymphoma, Follicular"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Sonja Berndt</AttName>
			<Institution>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Nathaniel Rothman</AttName>
			<Institution>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Stephen Chanock</AttName>
			<Institution>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Qing Lan</AttName>
			<Institution>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Lauren Teras</AttName>
			<Institution>Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Paolo Vineis</AttName>
			<Institution>MRC-HPA Centre for Environment and Health, School of Public Health, Imperial College London, London, United Kingdom</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Brenda Birmann</AttName>
			<Institution>Channing Division of Network Medicine, Department of Medicine, Brigham and Women&#39;s Hospital and Harvard Medical School, Boston, Massachusetts, USA</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Gianluca Severi</AttName>
			<Institution>Cancer Epidemiology Centre, Cancer Council Victoria, Carlton, Victoria, Australia</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Anne Zeleniuch-Jacquotte</AttName>
			<Institution>Department of Population Health, New York University School of Medicine, New York, New York, USA</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Mark Purdue</AttName>
			<Institution>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Angela R Brooks-Wilson</AttName>
			<Institution>Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Eve Roman</AttName>
			<Institution>Epidemiology and Genetics Unit, Department of Health Sciences, University of York, York, United Kingdom</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Pierluigi Cocco</AttName>
			<Institution>Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Monserrato, Cagliari, Italy</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Patricia Hartge</AttName>
			<Institution>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Bruce Armstrong</AttName>
			<Institution>Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Karin Smedby</AttName>
			<Institution>Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Christine Skibola</AttName>
			<Institution>School of Public Health, University of Alabama, Birmingham, Alabama, USA</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Yawei Zhang</AttName>
			<Institution>Department of Environmental Health Sciences, Yale School of Public Health, New Haven, Connecticut, USA</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Alain Monnereau</AttName>
			<Institution>Institut National de la Sante et de la Recherche Medicale (INSERM), Villejuif Cedex, France</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Alexandra Nieters</AttName>
			<Institution>Center of Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Hesse, Germany</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>James Cerhan</AttName>
			<Institution>Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Susan Slager</AttName>
			<Institution>Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA</Institution>
		</Header>
		<Header title="Study Representative">
			<AttName>Joseph Vijai</AttName>
			<Institution>Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA</Institution>
		</Header>
		<Header title="Genomics">
			<AttName>Zhaoming Wang</AttName>
			<Institution>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Intramural Research Program</AttName>
			<Institution>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyHistory><![CDATA[
<p>Genetic factors have long been implicated in the etiology of NHL through both family-based studies and case-control studies. A pooled analysis within the Interlymph Consortium showed that individuals with a first-degree relative with NHL, Hodgkin lymphoma, and leukemia had an increased risk of NHL, but the risks differed by subtype. In an effort to identify common variants associated with NHL, we conducted a large genome-wide association study within the framework of the InterLymph Consortium and NCI-sponsored Cohort Consortium. The studies included in this GWAS effort include:</p> <p> <ol> <li>Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study (ATBC)</li> <li>American Cancer Society Cancer Prevention Study-II Nutrition Cohort (CPS-II)</li> <li>European Prospective Investigation into Cancer, Chronic Diseases, Nutrition and Lifestyles (EPIC)</li> <li>Health Professionals Follow-up Study (HPFS)</li> <li>The Melbourne Collaborative Cohort Study (MCCS)</li> <li>Nurses&#39; Health Study (NHS)</li> <li>New York University Women&#39;s Health Study (NYU-WHS)</li> <li>Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)</li> <li>Women&#39;s Health Initiative (WHI)</li> <li>British Columbia Non-Hodgkin Lymphoma Study (BCCA)</li> <li>Epidemiology and Genetics Unit Lymphoma Case-Control study (ELCCS)</li> <li>Multicenter Italian study on gene-environment interactions in lymphoma etiology: translational aspects (Italian GxE)</li> <li>National Cancer Institute-Surveillance, Epidemiology, and End Results Interdisciplinary Case-Control Study of Non-Hodgkin&#39;s Lymphoma (NCI-SEER)</li> <li>NSW non-Hodgkin lymphoma study (NSW)</li> <li>Scandinavian Lymphoma Etiology Study (SCALE)</li> <li>Molecular Epidemiology of non-Hodgkin lymphoma (UCSF2)</li> <li>Population-based case-control study in Connecticut women (Yale)</li> <li>Environmental and genetic risks factors study in adult lymphoma (ENGELA)</li> <li>Epilymph case-control study in six European countries (EpiLymph)</li> <li>Iowa-Mayo SPORE Molecular Epidemiology Resource (Iowa-Mayo SPORE)</li> <li>Mayo Clinic Case-Control Study of NHL and CLL (Mayo Case-Control)</li> <li>Memorial-Sloan Kettering Lymphoproliferative disorders Study (MSKCC)</li> </ol> </p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-CA-IRB-NPU-GSO" longName="Disease-Specific (Cancer, IRB, NPU, GSO)"/>
		<ConsentGroup groupNum="2" shortName="DS-NHL-NPU-GSO" longName="Disease-Specific (non-Hodgkin Lymphoma, NPU, GSO)"/>
		<ConsentGroup groupNum="3" shortName="GRU-NPU-MDS" longName="General Research Use (NPU, MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000801.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>yes</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000801.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000801.v1.p1" FileName="NHL_DUC.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (Cancer, IRB, NPU, GSO)</ConsentName>
        <ConsentAbbrev>DS-CA-IRB-NPU-GSO</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Cancer. Requestor must provide documentation of local IRB approval. Use of the data is limited to not-for-profit organizations. Use of the data is limited to genetic studies only.</UseLimitation>
        <IrbRequired>Yes</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>Disease-Specific (non-Hodgkin Lymphoma, NPU, GSO)</ConsentName>
        <ConsentAbbrev>DS-NHL-NPU-GSO</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to non-Hodgkin Lymphoma. Use of the data is limited to not-for-profit organizations. Use of the data is limited to genetic studies only.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="3">
        <ConsentName>General Research Use (NPU, MDS)</ConsentName>
        <ConsentAbbrev>GRU-NPU-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification. Use of the data is limited to not-for-profit organizations. Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
